CompaniesArch Oncology

Arch Oncology

defunct
About

Defunct Company

Areas of Focus

Categories

Bankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (4)
View all

Total Trials

4

As Lead Sponsor

3

As Collaborator

1

Total Enrollment

161

By Phase

PHASE2: 2PHASE1/PHASE2: 2

By Status

COMPLETED: 3NOT_YET_RECRUITING: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
NCT01905150
NCT03834948
NCT06233877
Hover over trial bars to see details

Recent Trials

NCT06233877Lead Sponsor
Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic Cancer
PHASE2Not yet recruiting
60 participants
Started: Mar 15, 2024 · Completed: Jan 31, 2028
NCT04445701Lead Sponsor
Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
PHASE1/PHASE2Completed
10 participants
Started: Nov 30, 2020 · Completed: Nov 14, 2022
NCT03834948Lead Sponsor
AO-176 in Multiple Solid Tumor Malignancies
PHASE1/PHASE2Completed
57 participants
Started: Feb 4, 2019 · Completed: Feb 15, 2023
NCT01905150Collaborator
Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer
PHASE2Completed
34 participants
Started: Aug 13, 2014 · Completed: Jan 31, 2020
Funding History (1)
D
May 10, 2021
Filing